Category: Treatments

Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Posted on | Posted on John Murphy | Leave a Comment on Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Hironori Tsuchiya, Christos Rahiotis, Academic Editor and Nikolaos Gkantidis, Academic EditorDent J (Basel). 2023 Jun; 11(6): 140. Published online 2023 May 25. doi: 10.3390/dj11060140, PMCID: PMC10297082 PMID: 37366663 Abstract Since the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, treating taste and saliva secretory disorders associated with coronavirus disease 2019 (COVID-19) has become a critical issue. The aim of the […]

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Posted on | Posted on John Murphy | Leave a Comment on A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, Hassan Hartman, Alessandra Løchen, Thomas P. Peacock & Christopher Ruis Nature (2023) Cite this article Abstract Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus and many will be lethal; thus, molnupiravir-induced […]

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Posted on | Posted on John Murphy | Leave a Comment on Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD5; Alex J. Slandzicki, MD6; Stephen, C. Lim,  MD Jonathan Cohen, MD8;  David Kavtaradze, MD9,  Arch Amon, MD10, et. al for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. JAMA. 2023;329(11):888-897. doi:10.1001/jama.2023.1650 Question  Does ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo, shorten symptom duration among adult (≥30 years) outpatients with symptomatic […]

Simvastatin in Critically Ill Patients with Covid-19

Posted on | Posted on John Murphy | Leave a Comment on Simvastatin in Critically Ill Patients with Covid-19

November 2, 2023, NEJM Abstract BACKGROUND The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no statin (control) in critically ill patients with Covid-19 who were not receiving statins […]

COVID-19 Therapeutics for Nonhospitalized Patients

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 Therapeutics for Nonhospitalized Patients

Rajesh T. Gandhi, MD1; Preeti N. Malani, MD, MSJ2,3; Carlos del Rio, MD4, JAMA. 2022;327(7):617-618. doi:10.1001/jama.2022.0335 Substantial progress has been made in therapeutics for nonhospitalized patients with COVID-19, but supply of and access to treatment remain limited. This Viewpoint summarizes currently available therapeutics for nonhospitalized patients in the setting of the Omicron variant including principles for equitable allocation. Patients with mild or moderate COVID-19 […]

Hydroxychloroquine Associated With Lower COVID-19 Mortality: French Study

Posted on | Posted on John Murphy | Leave a Comment on Hydroxychloroquine Associated With Lower COVID-19 Mortality: French Study

NOV 03, 2023 – Authored by Zachary Stieber The Epoch Times  People who received hydroxychloroquine were less likely to die than those who did not, according to a new study. Just 0.8 percent of patients at a facility in France who received hydroxychloroquine (HCQ) and an antibiotic died, compared to 4.8 percent of patients who […]

European Regulator Confirms Pfizer Did Not Highlight DNA Sequence In COVID-19 Vaccine

Posted on | Posted on John Murphy | Leave a Comment on European Regulator Confirms Pfizer Did Not Highlight DNA Sequence In COVID-19 Vaccine

NOV 03, 2023 – Authored by Zachary Stieber The Epoch Times  Pfizer did not highlight a DNA sequence in its COVID-19 vaccine, a European regulator has confirmed. “While the full DNA sequence of the plasmid starting material was provided in the initial marketing authorization application for Comirnaty, the applicant did not specifically highlight the SV40 sequence,” the European […]

Narcolepsy following COVID‐19: A case report and review of potential mechanisms

Posted on | Posted on John Murphy | Leave a Comment on Narcolepsy following COVID‐19: A case report and review of potential mechanisms

Yazdani Roya, 1 Barzkar Farzaneh, 2 Almasi‐Dooghaee Mostafa, 1 Shojaie Mahsa, 1 and Zamani Babak 1 Clin Case Rep. 2023 Jun; 11(6): e7370. Published online 2023 May 25.https://doi.org/10.1002/ccr3.7370, PMCID: PMC10213711, PMID: 37251741 Abstract Key Clinical Message The immune activation in COVID‐19 may trigger narcolepsy in vulnerable patients. We suggest clinicians carefully evaluate patients with post‐COVID fatigue and hypersomnia for primary sleep disorders, specifically narcolepsy. Abstract The patient […]

FDA, CDC Hid Data On Spike In COVID Cases Among The Vaccinated: Documents

Posted on | Posted on John Murphy | Leave a Comment on FDA, CDC Hid Data On Spike In COVID Cases Among The Vaccinated: Documents

SEP 2023 – Authored by Zachary Stieber The Epoch Times COVID-19 cases among vaccinated seniors soared in 2021, according to newly disclosed data that was acquired by U.S. health agencies but not presented to the public. Syringes and vials of the Pfizer-BioNTech COVID-19 vaccine are prepared to be administered at a drive-up vaccination site from […]

COVID-19 Long-haul Fatigue Might be Similar to Chronic Fatigue Syndrome and Treated in a Similar Manner

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 Long-haul Fatigue Might be Similar to Chronic Fatigue Syndrome and Treated in a Similar Manner

There is no cure or approved treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). However, some symptoms can be treated or managed. Treating these symptoms might provide relief for some patients with ME/CFS but not others. Other strategies, like learning new ways to manage activity, can also be helpful. Patients, their families, and healthcare providers need […]